Last reviewed · How we verify
NCT05582707: ENRICHPLUS
Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone
Phase 2 trial testing Pioglitazone 15mg in Intracerebral Haemorrhage, Intraventricular in 1 participant. Terminated before completion.
19 September 2024
Quick facts
| Lead sponsor | University of Maryland, Baltimore |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 8 May 2023 |
| Primary completion | 19 September 2024 |
| Estimated completion | 19 September 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Pioglitazone 15mg — full drug profile →
Conditions studied
- Intracerebral Haemorrhage, Intraventricular — all drugs for Intracerebral Haemorrhage, Intraventricular →
Sponsor
University of Maryland, Baltimore
Who can join
Adults 18 to 80, any sex, with Intracerebral Haemorrhage, Intraventricular. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an exploratory single-center prospective study of 20 subjects with primary basal ganglia ICH who will receive early MIPS in combination with perioperative pioglitazone treatment. Outcomes will be compared to matched subjects with basal ganglia ICH who undergo MIPS alone as part of the ENRICH trial. This study will take approximately two years to complete.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05582707
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pioglitazone 15mg
Trials testing the same drug.
- NCT06594172 — Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy · Phase 2 · not yet recruiting
- NCT06164665 — Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude · Phase 4 · completed
- NCT04885712 — A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitu · Phase 3 · completed
- NCT04671056 — Drug Interaction Study of MGL-3196 With Pioglitazone · Phase 1 · completed
- NCT04883125 — Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment · Phase 2 · completed
Other University of Maryland, Baltimore trials
Trials by the same sponsor.
- NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
- NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
- NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
- NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
- NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05582707 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
- Last refreshed: 23 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05582707.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing